Ardigen, CVC collaborate to develop SARS-CoV-2 vaccine

13 July 2020 | News

To Apply Artificial Intelligence for Identification of T-cell Targets

Poland headquartered Ardigen and New Zealand based CVC (COVID-19 Vaccine Corporation) have announced that they entered a research collaboration aimed at the development of SARS-CoV-2 vaccine.

Ardigen's neoantigen prediction platform called "ArdImmune Vax" employs state of the art bioinformatics and Artificial Intelligence to identify an optimal set of neoantigens as targets for cancer vaccines or adoptive cell therapies.

This technology is also very well suited for the design of vaccines for infectious diseases. The core of the platform is a proprietary algorithm capable of predicting neoantigens' probability to elicit an immune response.

This joint research enables CVC to benefit from Ardigen's vaccine design technology by selecting which viral epitopes are the most suitable to boost cellular immune response.

Complementing humoral and cellular response in the vaccine design is expected to result in 2 strong lines of defense against the coronavirus. The approach is likely to be more effective than vaccines designed to create antibodies alone.